APPLE INC., 10-Q filed on 5/2/2025
Quarterly Report
v3.25.1
Cover Page - shares
shares in Thousands
6 Months Ended
Mar. 29, 2025
Apr. 18, 2025
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 29, 2025  
Document Transition Report false  
Entity File Number 001-36743  
Entity Registrant Name Apple Inc.  
Entity Incorporation, State or Country Code CA  
Entity Tax Identification Number 94-2404110  
Entity Address, Address Line One One Apple Park Way  
Entity Address, City or Town Cupertino  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 95014  
City Area Code 408  
Local Phone Number 996-1010  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   14,935,826
Amendment Flag false  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q2  
Entity Central Index Key 0000320193  
Current Fiscal Year End Date --09-27  
Common Stock, $0.00001 par value per share    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, $0.00001 par value per share  
Trading Symbol AAPL  
Security Exchange Name NASDAQ  
0.000% Notes due 2025    
Entity Information [Line Items]    
Title of 12(b) Security 0.000% Notes due 2025  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
0.875% Notes due 2025    
Entity Information [Line Items]    
Title of 12(b) Security 0.875% Notes due 2025  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
1.625% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.625% Notes due 2026  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
2.000% Notes due 2027    
Entity Information [Line Items]    
Title of 12(b) Security 2.000% Notes due 2027  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
1.375% Notes due 2029    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2029  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
3.050% Notes due 2029    
Entity Information [Line Items]    
Title of 12(b) Security 3.050% Notes due 2029  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
0.500% Notes due 2031    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2031  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
3.600% Notes due 2042    
Entity Information [Line Items]    
Title of 12(b) Security 3.600% Notes due 2042  
No Trading Symbol Flag true  
Security Exchange Name NASDAQ  
v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Net sales $ 95,359 $ 90,753 $ 219,659 $ 210,328
Cost of sales 50,492 48,482 116,517 113,202
Gross margin 44,867 42,271 103,142 97,126
Operating expenses:        
Research and development 8,550 7,903 16,818 15,599
Selling, general and administrative 6,728 6,468 13,903 13,254
Total operating expenses 15,278 14,371 30,721 28,853
Operating income 29,589 27,900 72,421 68,273
Other income/(expense), net (279) 158 (527) 108
Income before provision for income taxes 29,310 28,058 71,894 68,381
Provision for income taxes 4,530 4,422 10,784 10,829
Net income $ 24,780 $ 23,636 $ 61,110 $ 57,552
Earnings per share:        
Basic (in dollars per share) $ 1.65 $ 1.53 $ 4.06 $ 3.72
Diluted (in dollars per share) $ 1.65 $ 1.53 $ 4.05 $ 3.71
Shares used in computing earnings per share:        
Basic (in shares) 14,994,082 15,405,856 15,037,903 15,457,810
Diluted (in shares) 15,056,133 15,464,709 15,103,499 15,520,675
Products        
Net sales $ 68,714 $ 66,886 $ 166,674 $ 163,344
Cost of sales 44,030 42,424 103,477 100,864
Services        
Net sales 26,645 23,867 52,985 46,984
Cost of sales $ 6,462 $ 6,058 $ 13,040 $ 12,338
v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Statement of Comprehensive Income [Abstract]        
Net income $ 24,780 $ 23,636 $ 61,110 $ 57,552
Other comprehensive income/(loss):        
Change in foreign currency translation, net of tax 90 (322) (535) (14)
Change in unrealized gains/losses on derivative instruments, net of tax:        
Change in fair value of derivative instruments (318)   1,333  
Change in fair value of derivative instruments   456   (75)
Adjustment for net (gains)/losses realized and included in net income (628)   156  
Adjustment for net (gains)/losses realized and included in net income   232   (591)
Total change in unrealized gains/losses on derivative instruments (946)   1,489  
Total change in unrealized gains/losses on derivative instruments   688   (666)
Change in unrealized gains/losses on marketable debt securities, net of tax:        
Change in fair value of marketable debt securities 1,097 (7) (550) 3,038
Adjustment for net (gains)/losses realized and included in net income 185 59 405 134
Total change in unrealized gains/losses on marketable debt securities 1,282 52 (145) 3,172
Total other comprehensive income 426 418 809 2,492
Total comprehensive income $ 25,206 $ 24,054 $ 61,919 $ 60,044
v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Current assets:    
Cash and cash equivalents $ 28,162 $ 29,943
Marketable securities 20,336 35,228
Accounts receivable, net 26,136 33,410
Vendor non-trade receivables 23,662 32,833
Inventories 6,269 7,286
Other current assets 14,109 14,287
Total current assets 118,674 152,987
Non-current assets:    
Marketable securities 84,424 91,479
Property, plant and equipment, net 46,876 45,680
Other non-current assets 81,259 74,834
Total non-current assets 212,559 211,993
Total assets 331,233 364,980
Current liabilities:    
Accounts payable 54,126 68,960
Other current liabilities 61,849 78,304
Deferred revenue 8,976 8,249
Commercial paper 5,982 9,967
Term debt 13,638 10,912
Total current liabilities 144,571 176,392
Non-current liabilities:    
Term debt 78,566 85,750
Other non-current liabilities 41,300 45,888
Total non-current liabilities 119,866 131,638
Total liabilities 264,437 308,030
Commitments and contingencies
Shareholders’ equity:    
Common stock and additional paid-in capital, $0.00001 par value: 50,400,000 shares authorized; 14,939,315 and 15,116,786 shares issued and outstanding, respectively 88,711 83,276
Accumulated deficit (15,552) (19,154)
Accumulated other comprehensive loss (6,363) (7,172)
Total shareholders’ equity 66,796 56,950
Total liabilities and shareholders’ equity $ 331,233 $ 364,980
v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Mar. 29, 2025
Sep. 28, 2024
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Common stock, shares authorized (in shares) 50,400,000,000 50,400,000,000
Common stock, shares issued (in shares) 14,939,315,000 15,116,786,000
Common stock, shares outstanding (in shares) 14,939,315,000 15,116,786,000
v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Millions
Total
Common stock and additional paid-in capital
Retained earnings/(Accumulated deficit)
Accumulated other comprehensive income/(loss)
Beginning balances at Sep. 30, 2023 $ 62,146 $ 73,812 $ (214) $ (11,452)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued   752    
Common stock withheld related to net share settlement of equity awards   (1,882) (1,089)  
Share-based compensation   6,133    
Net income 57,552   57,552  
Dividends and dividend equivalents declared     (7,520)  
Common stock repurchased     (44,390)  
Other comprehensive income 2,492     2,492
Ending balances at Mar. 30, 2024 $ 74,194 78,815 4,339 (8,960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) $ 0.48      
Beginning balances at Dec. 30, 2023 $ 74,100 75,236 8,242 (9,378)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued   752    
Common stock withheld related to net share settlement of equity awards   (222) (71)  
Share-based compensation   3,049    
Net income 23,636   23,636  
Dividends and dividend equivalents declared     (3,746)  
Common stock repurchased     (23,722)  
Other comprehensive income 418     418
Ending balances at Mar. 30, 2024 $ 74,194 78,815 4,339 (8,960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) $ 0.24      
Beginning balances at Sep. 28, 2024 $ 56,950 83,276 (19,154) (7,172)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued   825    
Common stock withheld related to net share settlement of equity awards   (2,097) (1,187)  
Share-based compensation   6,707    
Net income 61,110   61,110  
Dividends and dividend equivalents declared     (7,613)  
Common stock repurchased (48,300)   (48,708)  
Other comprehensive income 809     809
Ending balances at Mar. 29, 2025 $ 66,796 88,711 (15,552) (6,363)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) $ 0.50      
Beginning balances at Dec. 28, 2024 $ 66,758 84,768 (11,221) (6,789)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued   825    
Common stock withheld related to net share settlement of equity awards   (206) (85)  
Share-based compensation   3,324    
Net income 24,780   24,780  
Dividends and dividend equivalents declared     (3,794)  
Common stock repurchased     (25,232)  
Other comprehensive income 426     426
Ending balances at Mar. 29, 2025 $ 66,796 $ 88,711 $ (15,552) $ (6,363)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Dividends and dividend equivalents declared per share or RSU (in dollars per share or RSU) $ 0.25      
v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Statement of Cash Flows [Abstract]    
Cash, cash equivalents, and restricted cash and cash equivalents, beginning balances $ 29,943 $ 30,737
Operating activities:    
Net income 61,110 57,552
Adjustments to reconcile net income to cash generated by operating activities:    
Depreciation and amortization 5,741 5,684
Share-based compensation expense 6,512 5,961
Other (2,217) (1,971)
Changes in operating assets and liabilities:    
Accounts receivable, net 7,266 7,727
Vendor non-trade receivables 9,171 12,164
Inventories 858 53
Other current and non-current assets (4,371) (4,438)
Accounts payable (14,604) (16,710)
Other current and non-current liabilities (15,579) (3,437)
Cash generated by operating activities 53,887 62,585
Investing activities:    
Purchases of marketable securities (12,442) (25,042)
Proceeds from maturities of marketable securities 26,587 27,462
Proceeds from sales of marketable securities 5,210 4,314
Payments for acquisition of property, plant and equipment (6,011) (4,388)
Other (635) (729)
Cash generated by investing activities 12,709 1,617
Financing activities:    
Payments for taxes related to net share settlement of equity awards (3,205) (2,875)
Payments for dividends and dividend equivalents (7,614) (7,535)
Repurchases of common stock (49,504) (43,344)
Repayments of term debt (4,009) (3,150)
Repayments of commercial paper, net (3,968) (3,982)
Other (77) (132)
Cash used in financing activities (68,377) (61,018)
Increase/(Decrease) in cash, cash equivalents, and restricted cash and cash equivalents (1,781) 3,184
Cash, cash equivalents, and restricted cash and cash equivalents, ending balances 28,162 33,921
Supplemental cash flow disclosure:    
Cash paid for income taxes, net $ 31,683 $ 14,531
v3.25.1
Summary of Significant Accounting Policies
6 Months Ended
Mar. 29, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation and Preparation
The condensed consolidated financial statements include the accounts of Apple Inc. and its wholly owned subsidiaries (collectively “Apple” or the “Company”). In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles (“GAAP”) requires the use of management estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended September 28, 2024 (the “2024 Form 10-K”).
The Company’s fiscal year is the 52- or 53-week period that ends on the last Saturday of September. An additional week is included in the first fiscal quarter every five or six years to realign the Company’s fiscal quarters with calendar quarters. The Company’s fiscal years 2025 and 2024 span 52 weeks each. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years.
v3.25.1
Revenue
6 Months Ended
Mar. 29, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table shows disaggregated net sales, as well as the portion of total net sales that was previously deferred, for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
iPhone®
$46,841 $45,963 $115,979 $115,665 
Mac®
7,949 7,451 16,936 15,231 
iPad®
6,402 5,559 14,490 12,582 
Wearables, Home and Accessories7,522 7,913 19,269 19,866 
Services26,645 23,867 52,985 46,984 
Total net sales$95,359 $90,753 $219,659 $210,328 
Portion of total net sales that was included in deferred revenue as of the beginning of the period
$3,672 $3,282 $5,440 $5,135 
The Company’s proportion of net sales by disaggregated revenue source was generally consistent for each reportable segment in Note 10, “Segment Information and Geographic Data” for the three- and six-month periods ended March 29, 2025 and March 30, 2024, except in Greater China, where iPhone revenue represented a moderately higher proportion of net sales.
As of March 29, 2025 and September 28, 2024, the Company had total deferred revenue of $13.6 billion and $12.8 billion, respectively. As of March 29, 2025, the Company expects 66% of total deferred revenue to be realized in less than a year, 24% within one-to-two years, 9% within two-to-three years and 1% in greater than three years.
v3.25.1
Earnings Per Share
6 Months Ended
Mar. 29, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table shows the computation of basic and diluted earnings per share for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (net income in millions and shares in thousands):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Numerator:
Net income$24,780 $23,636 $61,110 $57,552 
Denominator:
Weighted-average basic shares outstanding14,994,082 15,405,856 15,037,903 15,457,810 
Effect of dilutive share-based awards
62,051 58,853 65,596 62,865 
Weighted-average diluted shares15,056,133 15,464,709 15,103,499 15,520,675 
Basic earnings per share$1.65 $1.53 $4.06 $3.72 
Diluted earnings per share$1.65 $1.53 $4.05 $3.71 
v3.25.1
Financial Instruments
6 Months Ended
Mar. 29, 2025
Financial Instruments [Abstract]  
Financial Instruments Financial Instruments
Cash, Cash Equivalents and Marketable Securities
The following tables show the Company’s cash, cash equivalents and marketable securities by significant investment category as of March 29, 2025 and September 28, 2024 (in millions):
March 29, 2025
Adjusted
Cost
Unrealized
Gains
Unrealized
Losses
Fair
Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-Current
Marketable
Securities
Cash$25,061 $— $— $25,061 $25,061 $— $— 
Level 1:
Money market funds1,132 — — 1,132 1,132 — — 
Mutual funds
612 81 (11)682 — 682 — 
Subtotal1,744 81 (11)1,814 1,132 682 — 
Level 2 (1):
U.S. Treasury securities14,509 24 (445)14,088 124 4,088 9,876 
U.S. agency securities4,889 — (233)4,656 66 2,004 2,586 
Non-U.S. government securities6,351 29 (625)5,755 — 529 5,226 
Certificates of deposit and time deposits1,744 — — 1,744 1,731 — 13 
Commercial paper— — — — 
Corporate debt securities55,743 121 (1,672)54,192 48 12,412 41,732 
Municipal securities303 — (5)298 — 170 128 
Mortgage- and asset-backed securities26,742 121 (1,551)25,312 — 449 24,863 
Subtotal110,283 295 (4,531)106,047 1,969 19,654 84,424 
Total
$137,088 $376 $(4,542)$132,922 $28,162 $20,336 $84,424 
September 28, 2024
Adjusted
Cost
Unrealized
Gains
Unrealized
Losses
Fair
Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-Current
Marketable
Securities
Cash$27,199 $— $— $27,199 $27,199 $— $— 
Level 1:
Money market funds778 — — 778 778 — — 
Mutual funds
515 105 (3)617 — 617 — 
Subtotal1,293 105 (3)1,395 778 617 — 
Level 2 (1):
U.S. Treasury securities16,150 45 (516)15,679 212 4,087 11,380 
U.S. agency securities5,431 — (272)5,159 155 703 4,301 
Non-U.S. government securities17,959 93 (484)17,568 1,158 10,810 5,600 
Certificates of deposit and time deposits873 — — 873 387 478 
Commercial paper1,066 — — 1,066 28 1,038 — 
Corporate debt securities65,622 270 (1,953)63,939 26 16,027 47,886 
Municipal securities412 — (7)405 — 190 215 
Mortgage- and asset-backed securities24,595 175 (1,403)23,367 — 1,278 22,089 
Subtotal132,108 583 (4,635)128,056 1,966 34,611 91,479 
Total (2)(3)
$160,600 $688 $(4,638)$156,650 $29,943 $35,228 $91,479 
(1)The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
(2)As of September 28, 2024, cash and cash equivalents included $2.6 billion held in escrow and restricted from general use. These restricted cash and cash equivalents were designated to settle the Company’s obligation related to the 2016 European Commission (the “Commission”) decision that Ireland granted state aid to the Company (the “State Aid Decision”), which was confirmed during the fourth quarter of 2024 by the European Court of Justice in a reversal of the 2020 judgment of the European General Court.
(3)As of September 28, 2024, current marketable securities included $13.2 billion held in escrow and restricted from general use. These restricted marketable securities were designated to settle the Company’s obligation related to the State Aid Decision.
As of March 29, 2025, 83% of the Company’s non-current marketable debt securities other than mortgage- and asset-backed securities had maturities between 1 and 5 years, 13% between 5 and 10 years, and 4% greater than 10 years. As of March 29, 2025, 13% of the Company’s non-current mortgage- and asset-backed securities had maturities between 1 and 5 years, 10% between 5 and 10 years, and 77% greater than 10 years.
Derivative Instruments and Hedging
The Company may use derivative instruments to partially offset its business exposure to foreign exchange and interest rate risk. However, the Company may choose not to hedge certain exposures for a variety of reasons, including accounting considerations or the prohibitive economic cost of hedging particular exposures. There can be no assurance the hedges will offset more than a portion of the financial impact resulting from movements in foreign exchange or interest rates.
Foreign Exchange Rate Risk
To protect gross margins from fluctuations in foreign exchange rates, the Company may use forwards, options or other instruments, and may designate these instruments as cash flow hedges. The Company generally hedges portions of its forecasted foreign currency exposure associated with revenue and inventory purchases, typically for up to 12 months.
To protect the Company’s foreign currency–denominated term debt or marketable securities from fluctuations in foreign exchange rates, the Company may use forwards, cross-currency swaps or other instruments. The Company designates these instruments as either cash flow or fair value hedges. As of March 29, 2025, the maximum length of time over which the Company is hedging its exposure to the variability in future cash flows for term debt–related foreign currency transactions is 17 years.
The Company may also use derivative instruments that are not designated as accounting hedges to protect gross margins from certain fluctuations in foreign exchange rates, as well as to offset a portion of the foreign currency gains and losses generated by the remeasurement of certain assets and liabilities denominated in non-functional currencies.
Interest Rate Risk
To protect the Company’s term debt or marketable securities from fluctuations in interest rates, the Company may use interest rate swaps, options or other instruments. The Company designates these instruments as either cash flow or fair value hedges.
The notional amounts of the Company’s outstanding derivative instruments as of March 29, 2025 and September 28, 2024 were as follows (in millions):
March 29,
2025
September 28,
2024
Derivative instruments designated as accounting hedges:
Foreign exchange contracts$68,533 $64,069 
Interest rate contracts$14,575 $14,575 
Derivative instruments not designated as accounting hedges:
Foreign exchange contracts$68,388 $91,493 
As of March 29, 2025 and September 28, 2024, the carrying amount of the Company’s current and non-current term debt subject to fair value hedges was $13.4 billion and $13.5 billion, respectively.
Accounts Receivable
Trade Receivables
The Company’s third-party cellular network carriers accounted for 37% and 38% of total trade receivables as of March 29, 2025 and September 28, 2024, respectively. The Company requires third-party credit support or collateral from certain customers to limit credit risk.
Vendor Non-Trade Receivables
The Company has non-trade receivables from certain of its manufacturing vendors resulting from the sale of components to these vendors who manufacture subassemblies or assemble final products for the Company. The Company purchases these components directly from suppliers. The Company does not reflect the sale of these components in products net sales. Rather, the Company recognizes any gain on these sales as a reduction of products cost of sales when the related final products are sold by the Company. As of March 29, 2025, the Company had two vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 49% and 19%. As of September 28, 2024, the Company had two vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 44% and 23%.
v3.25.1
Condensed Consolidated Financial Statement Details
6 Months Ended
Mar. 29, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Condensed Consolidated Financial Statement Details Condensed Consolidated Financial Statement Details
The following tables show the Company’s condensed consolidated financial statement details as of March 29, 2025 and September 28, 2024 (in millions):
Inventories
March 29,
2025
September 28,
2024
Components
$2,673 $3,627 
Finished goods
3,596 3,659 
Total inventories
$6,269 $7,286 
Property, Plant and Equipment, Net
March 29,
2025
September 28,
2024
Gross property, plant and equipment$121,179 $119,128 
Accumulated depreciation
(74,303)(73,448)
Total property, plant and equipment, net$46,876 $45,680 
v3.25.1
Debt
6 Months Ended
Mar. 29, 2025
Debt Disclosure [Abstract]  
Debt Debt
Commercial Paper
The Company issues unsecured short-term promissory notes pursuant to a commercial paper program. The Company uses net proceeds from the commercial paper program for general corporate purposes, including dividends and share repurchases. As of March 29, 2025 and September 28, 2024, the Company had $6.0 billion and $10.0 billion of commercial paper outstanding, respectively.
Term Debt
As of March 29, 2025 and September 28, 2024, the Company had outstanding fixed-rate notes with varying maturities for an aggregate carrying amount of $92.2 billion and $96.7 billion, respectively (collectively the “Notes”). As of March 29, 2025 and September 28, 2024, the fair value of the Company’s Notes, based on Level 2 inputs, was $80.9 billion and $88.4 billion, respectively.
v3.25.1
Shareholders' Equity
6 Months Ended
Mar. 29, 2025
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Share Repurchase Program
During the six months ended March 29, 2025, the Company repurchased 208 million shares of its common stock for $48.3 billion. The Company’s share repurchase program does not obligate the Company to acquire a minimum amount of shares. Under the program, shares may be repurchased in privately negotiated or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
v3.25.1
Share-Based Compensation
6 Months Ended
Mar. 29, 2025
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Restricted Stock Units
A summary of the Company’s RSU activity and related information for the six months ended March 29, 2025 is as follows:
Number of
RSUs
(in thousands)
Weighted-Average
Grant-Date Fair
Value Per RSU
Balance as of September 28, 2024163,326 $158.73 
RSUs granted63,378 $228.10 
RSUs vested(39,177)$148.90 
RSUs canceled(4,181)$177.54 
Balance as of March 29, 2025183,346 $184.38 
The total vesting-date fair value of RSUs was $906 million and $9.3 billion for the three- and six-month periods ended March 29, 2025, respectively, and was $821 million and $8.6 billion for the three- and six-month periods ended March 30, 2024, respectively.
Share-Based Compensation
The following table shows share-based compensation expense and the related income tax benefit included in the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Share-based compensation expense$3,226 $2,964 $6,512 $5,961 
Income tax benefit related to share-based compensation expense$(743)$(663)$(2,075)$(1,898)
As of March 29, 2025, the total unrecognized compensation cost related to outstanding RSUs was $26.3 billion, which the Company expects to recognize over a weighted-average period of 2.7 years.
v3.25.1
Contingencies
6 Months Ended
Mar. 29, 2025
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and that have not been fully resolved. The outcome of litigation is inherently uncertain. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss, or a material loss greater than a recorded accrual, concerning loss contingencies for asserted legal and other claims.
v3.25.1
Segment Information and Geographic Data
6 Months Ended
Mar. 29, 2025
Segment Reporting [Abstract]  
Segment Information and Geographic Data Segment Information and Geographic Data
The following table shows information by reportable segment for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Americas:
Net sales$40,315 $37,273 $92,963 $87,703 
Operating income$16,774 $15,074 $38,283 $35,431 
Europe:
Net sales$24,454 $24,123 $58,315 $54,520 
Operating income$10,316 $9,991 $24,923 $22,702 
Greater China:
Net sales$16,002 $16,372 $34,515 $37,191 
Operating income$6,626 $6,700 $14,786 $15,322 
Japan:
Net sales$7,298 $6,262 $16,285 $14,029 
Operating income$3,434 $3,135 $7,748 $6,954 
Rest of Asia Pacific:
Net sales$7,290 $6,723 $17,581 $16,885 
Operating income$2,986 $2,806 $7,570 $7,385 
A reconciliation of the Company’s segment operating income to the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 29, 2025 and March 30, 2024 is as follows (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Segment operating income$40,136 $37,706 $93,310 $87,794 
Research and development expense(8,550)(7,903)(16,818)(15,599)
Other corporate expenses, net(1,997)(1,903)(4,071)(3,922)
Total operating income$29,589 $27,900 $72,421 $68,273 
v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Pay vs Performance Disclosure        
Net income $ 24,780 $ 23,636 $ 61,110 $ 57,552
v3.25.1
Insider Trading Arrangements
3 Months Ended
Mar. 29, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.1
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Mar. 29, 2025
Accounting Policies [Abstract]  
Basis of Presentation and Preparation
Basis of Presentation and Preparation
The condensed consolidated financial statements include the accounts of Apple Inc. and its wholly owned subsidiaries (collectively “Apple” or the “Company”). In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles (“GAAP”) requires the use of management estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended September 28, 2024 (the “2024 Form 10-K”).
Fiscal Period
The Company’s fiscal year is the 52- or 53-week period that ends on the last Saturday of September. An additional week is included in the first fiscal quarter every five or six years to realign the Company’s fiscal quarters with calendar quarters. The Company’s fiscal years 2025 and 2024 span 52 weeks each. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years.
Fair Value Measurements The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
v3.25.1
Revenue (Tables)
6 Months Ended
Mar. 29, 2025
Revenue from Contract with Customer [Abstract]  
Disaggregated Net Sales and Portion of Net Sales That Was Previously Deferred
The following table shows disaggregated net sales, as well as the portion of total net sales that was previously deferred, for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
iPhone®
$46,841 $45,963 $115,979 $115,665 
Mac®
7,949 7,451 16,936 15,231 
iPad®
6,402 5,559 14,490 12,582 
Wearables, Home and Accessories7,522 7,913 19,269 19,866 
Services26,645 23,867 52,985 46,984 
Total net sales$95,359 $90,753 $219,659 $210,328 
Portion of total net sales that was included in deferred revenue as of the beginning of the period
$3,672 $3,282 $5,440 $5,135 
v3.25.1
Earnings Per Share (Tables)
6 Months Ended
Mar. 29, 2025
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share
The following table shows the computation of basic and diluted earnings per share for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (net income in millions and shares in thousands):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Numerator:
Net income$24,780 $23,636 $61,110 $57,552 
Denominator:
Weighted-average basic shares outstanding14,994,082 15,405,856 15,037,903 15,457,810 
Effect of dilutive share-based awards
62,051 58,853 65,596 62,865 
Weighted-average diluted shares15,056,133 15,464,709 15,103,499 15,520,675 
Basic earnings per share$1.65 $1.53 $4.06 $3.72 
Diluted earnings per share$1.65 $1.53 $4.05 $3.71 
v3.25.1
Financial Instruments (Tables)
6 Months Ended
Mar. 29, 2025
Financial Instruments [Abstract]  
Cash, Cash Equivalents and Marketable Securities by Significant Investment Category
The following tables show the Company’s cash, cash equivalents and marketable securities by significant investment category as of March 29, 2025 and September 28, 2024 (in millions):
March 29, 2025
Adjusted
Cost
Unrealized
Gains
Unrealized
Losses
Fair
Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-Current
Marketable
Securities
Cash$25,061 $— $— $25,061 $25,061 $— $— 
Level 1:
Money market funds1,132 — — 1,132 1,132 — — 
Mutual funds
612 81 (11)682 — 682 — 
Subtotal1,744 81 (11)1,814 1,132 682 — 
Level 2 (1):
U.S. Treasury securities14,509 24 (445)14,088 124 4,088 9,876 
U.S. agency securities4,889 — (233)4,656 66 2,004 2,586 
Non-U.S. government securities6,351 29 (625)5,755 — 529 5,226 
Certificates of deposit and time deposits1,744 — — 1,744 1,731 — 13 
Commercial paper— — — — 
Corporate debt securities55,743 121 (1,672)54,192 48 12,412 41,732 
Municipal securities303 — (5)298 — 170 128 
Mortgage- and asset-backed securities26,742 121 (1,551)25,312 — 449 24,863 
Subtotal110,283 295 (4,531)106,047 1,969 19,654 84,424 
Total
$137,088 $376 $(4,542)$132,922 $28,162 $20,336 $84,424 
September 28, 2024
Adjusted
Cost
Unrealized
Gains
Unrealized
Losses
Fair
Value
Cash and
Cash
Equivalents
Current
Marketable
Securities
Non-Current
Marketable
Securities
Cash$27,199 $— $— $27,199 $27,199 $— $— 
Level 1:
Money market funds778 — — 778 778 — — 
Mutual funds
515 105 (3)617 — 617 — 
Subtotal1,293 105 (3)1,395 778 617 — 
Level 2 (1):
U.S. Treasury securities16,150 45 (516)15,679 212 4,087 11,380 
U.S. agency securities5,431 — (272)5,159 155 703 4,301 
Non-U.S. government securities17,959 93 (484)17,568 1,158 10,810 5,600 
Certificates of deposit and time deposits873 — — 873 387 478 
Commercial paper1,066 — — 1,066 28 1,038 — 
Corporate debt securities65,622 270 (1,953)63,939 26 16,027 47,886 
Municipal securities412 — (7)405 — 190 215 
Mortgage- and asset-backed securities24,595 175 (1,403)23,367 — 1,278 22,089 
Subtotal132,108 583 (4,635)128,056 1,966 34,611 91,479 
Total (2)(3)
$160,600 $688 $(4,638)$156,650 $29,943 $35,228 $91,479 
(1)The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
(2)As of September 28, 2024, cash and cash equivalents included $2.6 billion held in escrow and restricted from general use. These restricted cash and cash equivalents were designated to settle the Company’s obligation related to the 2016 European Commission (the “Commission”) decision that Ireland granted state aid to the Company (the “State Aid Decision”), which was confirmed during the fourth quarter of 2024 by the European Court of Justice in a reversal of the 2020 judgment of the European General Court.
(3)As of September 28, 2024, current marketable securities included $13.2 billion held in escrow and restricted from general use. These restricted marketable securities were designated to settle the Company’s obligation related to the State Aid Decision.
Notional Amounts of Outstanding Derivative Instruments
The notional amounts of the Company’s outstanding derivative instruments as of March 29, 2025 and September 28, 2024 were as follows (in millions):
March 29,
2025
September 28,
2024
Derivative instruments designated as accounting hedges:
Foreign exchange contracts$68,533 $64,069 
Interest rate contracts$14,575 $14,575 
Derivative instruments not designated as accounting hedges:
Foreign exchange contracts$68,388 $91,493 
v3.25.1
Condensed Consolidated Financial Statement Details (Tables)
6 Months Ended
Mar. 29, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Inventories
Inventories
March 29,
2025
September 28,
2024
Components
$2,673 $3,627 
Finished goods
3,596 3,659 
Total inventories
$6,269 $7,286 
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net
March 29,
2025
September 28,
2024
Gross property, plant and equipment$121,179 $119,128 
Accumulated depreciation
(74,303)(73,448)
Total property, plant and equipment, net$46,876 $45,680 
v3.25.1
Share-Based Compensation (Tables)
6 Months Ended
Mar. 29, 2025
Share-Based Payment Arrangement [Abstract]  
Restricted Stock Unit Activity
A summary of the Company’s RSU activity and related information for the six months ended March 29, 2025 is as follows:
Number of
RSUs
(in thousands)
Weighted-Average
Grant-Date Fair
Value Per RSU
Balance as of September 28, 2024163,326 $158.73 
RSUs granted63,378 $228.10 
RSUs vested(39,177)$148.90 
RSUs canceled(4,181)$177.54 
Balance as of March 29, 2025183,346 $184.38 
Share-Based Compensation Expense and the Related Income Tax Benefit
The following table shows share-based compensation expense and the related income tax benefit included in the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Share-based compensation expense$3,226 $2,964 $6,512 $5,961 
Income tax benefit related to share-based compensation expense$(743)$(663)$(2,075)$(1,898)
v3.25.1
Segment Information and Geographic Data (Tables)
6 Months Ended
Mar. 29, 2025
Segment Reporting [Abstract]  
Information by Reportable Segment
The following table shows information by reportable segment for the three- and six-month periods ended March 29, 2025 and March 30, 2024 (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Americas:
Net sales$40,315 $37,273 $92,963 $87,703 
Operating income$16,774 $15,074 $38,283 $35,431 
Europe:
Net sales$24,454 $24,123 $58,315 $54,520 
Operating income$10,316 $9,991 $24,923 $22,702 
Greater China:
Net sales$16,002 $16,372 $34,515 $37,191 
Operating income$6,626 $6,700 $14,786 $15,322 
Japan:
Net sales$7,298 $6,262 $16,285 $14,029 
Operating income$3,434 $3,135 $7,748 $6,954 
Rest of Asia Pacific:
Net sales$7,290 $6,723 $17,581 $16,885 
Operating income$2,986 $2,806 $7,570 $7,385 
Reconciliation of Segment Operating Income to the Condensed Consolidated Statements of Operations
A reconciliation of the Company’s segment operating income to the Condensed Consolidated Statements of Operations for the three- and six-month periods ended March 29, 2025 and March 30, 2024 is as follows (in millions):
Three Months EndedSix Months Ended
March 29,
2025
March 30,
2024
March 29,
2025
March 30,
2024
Segment operating income$40,136 $37,706 $93,310 $87,794 
Research and development expense(8,550)(7,903)(16,818)(15,599)
Other corporate expenses, net(1,997)(1,903)(4,071)(3,922)
Total operating income$29,589 $27,900 $72,421 $68,273 
v3.25.1
Revenue - Disaggregated Net Sales and Portion of Net Sales That Was Previously Deferred (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Disaggregation of Revenue [Line Items]        
Net sales $ 95,359 $ 90,753 $ 219,659 $ 210,328
Portion of total net sales that was included in deferred revenue as of the beginning of the period 3,672 3,282 5,440 5,135
iPhone        
Disaggregation of Revenue [Line Items]        
Net sales 46,841 45,963 115,979 115,665
Mac        
Disaggregation of Revenue [Line Items]        
Net sales 7,949 7,451 16,936 15,231
iPad        
Disaggregation of Revenue [Line Items]        
Net sales 6,402 5,559 14,490 12,582
Wearables, Home and Accessories        
Disaggregation of Revenue [Line Items]        
Net sales 7,522 7,913 19,269 19,866
Services        
Disaggregation of Revenue [Line Items]        
Net sales $ 26,645 $ 23,867 $ 52,985 $ 46,984
v3.25.1
Revenue - Additional Information (Details) - USD ($)
$ in Billions
Mar. 29, 2025
Sep. 28, 2024
Revenue from Contract with Customer [Abstract]    
Total deferred revenue $ 13.6 $ 12.8
v3.25.1
Revenue - Deferred Revenue, Expected Timing of Realization (Details)
Mar. 29, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-30  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Deferred revenue, expected timing of realization, percentage 66.00%
Deferred revenue, expected timing of realization, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Deferred revenue, expected timing of realization, percentage 24.00%
Deferred revenue, expected timing of realization, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-03-28  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Deferred revenue, expected timing of realization, percentage 9.00%
Deferred revenue, expected timing of realization, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-04-02  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Deferred revenue, expected timing of realization, percentage 1.00%
Deferred revenue, expected timing of realization, period 1 year
v3.25.1
Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Numerator:        
Net income $ 24,780 $ 23,636 $ 61,110 $ 57,552
Denominator:        
Weighted-average basic shares outstanding (in shares) 14,994,082 15,405,856 15,037,903 15,457,810
Effect of dilutive share-based awards (in shares) 62,051 58,853 65,596 62,865
Weighted-average diluted shares (in shares) 15,056,133 15,464,709 15,103,499 15,520,675
Basic earnings per share (in dollars per share) $ 1.65 $ 1.53 $ 4.06 $ 3.72
Diluted earnings per share (in dollars per share) $ 1.65 $ 1.53 $ 4.05 $ 3.71
v3.25.1
Financial Instruments - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Marketable Securities [Line Items]    
Cash, Cash Equivalents and Marketable Securities, Adjusted Cost $ 137,088 $ 160,600
Cash Equivalents and Marketable Securities, Unrealized Gains 376 688
Cash Equivalents and Marketable Securities, Unrealized Losses (4,542) (4,638)
Cash, Cash Equivalents and Marketable Securities, Fair Value 132,922 156,650
Cash and Cash Equivalents 28,162 29,943
Current Marketable Securities 20,336 35,228
Non-Current Marketable Securities 84,424 91,479
Unfavorable investigation outcome, EU State Aid rules    
Marketable Securities [Line Items]    
Cash and cash equivalents held in escrow and restricted from general use   2,600
Current marketable securities held in escrow and restricted from general use   13,200
Level 1    
Marketable Securities [Line Items]    
Marketable Securities, Equity, Adjusted Cost 1,744 1,293
Marketable Securities, Equity, Unrealized Gains 81 105
Marketable Securities, Equity, Unrealized Losses (11) (3)
Marketable Securities, Equity, Fair Value 1,814 1,395
Cash and Cash Equivalents 1,132 778
Current Marketable Securities 682 617
Non-Current Marketable Securities 0 0
Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 110,283 132,108
Marketable Securities, Debt, Unrealized Gains 295 583
Marketable Securities, Debt, Unrealized Losses (4,531) (4,635)
Marketable Securities, Debt, Fair Value 106,047 128,056
Cash and Cash Equivalents 1,969 1,966
Current Marketable Securities 19,654 34,611
Non-Current Marketable Securities 84,424 91,479
Cash    
Marketable Securities [Line Items]    
Cash 25,061 27,199
Cash and Cash Equivalents 25,061 27,199
Money market funds | Level 1    
Marketable Securities [Line Items]    
Marketable Securities, Equity, Adjusted Cost 1,132 778
Marketable Securities, Equity, Unrealized Gains 0 0
Marketable Securities, Equity, Unrealized Losses 0 0
Marketable Securities, Equity, Fair Value 1,132 778
Cash and Cash Equivalents 1,132 778
Current Marketable Securities 0 0
Non-Current Marketable Securities 0 0
Mutual funds | Level 1    
Marketable Securities [Line Items]    
Marketable Securities, Equity, Adjusted Cost 612 515
Marketable Securities, Equity, Unrealized Gains 81 105
Marketable Securities, Equity, Unrealized Losses (11) (3)
Marketable Securities, Equity, Fair Value 682 617
Cash and Cash Equivalents 0 0
Current Marketable Securities 682 617
Non-Current Marketable Securities 0 0
U.S. Treasury securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 14,509 16,150
Marketable Securities, Debt, Unrealized Gains 24 45
Marketable Securities, Debt, Unrealized Losses (445) (516)
Marketable Securities, Debt, Fair Value 14,088 15,679
Cash and Cash Equivalents 124 212
Current Marketable Securities 4,088 4,087
Non-Current Marketable Securities 9,876 11,380
U.S. agency securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 4,889 5,431
Marketable Securities, Debt, Unrealized Gains 0 0
Marketable Securities, Debt, Unrealized Losses (233) (272)
Marketable Securities, Debt, Fair Value 4,656 5,159
Cash and Cash Equivalents 66 155
Current Marketable Securities 2,004 703
Non-Current Marketable Securities 2,586 4,301
Non-U.S. government securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 6,351 17,959
Marketable Securities, Debt, Unrealized Gains 29 93
Marketable Securities, Debt, Unrealized Losses (625) (484)
Marketable Securities, Debt, Fair Value 5,755 17,568
Cash and Cash Equivalents 0 1,158
Current Marketable Securities 529 10,810
Non-Current Marketable Securities 5,226 5,600
Certificates of deposit and time deposits | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 1,744 873
Marketable Securities, Debt, Unrealized Gains 0 0
Marketable Securities, Debt, Unrealized Losses 0 0
Marketable Securities, Debt, Fair Value 1,744 873
Cash and Cash Equivalents 1,731 387
Current Marketable Securities 0 478
Non-Current Marketable Securities 13 8
Commercial paper | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 2 1,066
Marketable Securities, Debt, Unrealized Gains 0 0
Marketable Securities, Debt, Unrealized Losses 0 0
Marketable Securities, Debt, Fair Value 2 1,066
Cash and Cash Equivalents 0 28
Current Marketable Securities 2 1,038
Non-Current Marketable Securities 0 0
Corporate debt securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 55,743 65,622
Marketable Securities, Debt, Unrealized Gains 121 270
Marketable Securities, Debt, Unrealized Losses (1,672) (1,953)
Marketable Securities, Debt, Fair Value 54,192 63,939
Cash and Cash Equivalents 48 26
Current Marketable Securities 12,412 16,027
Non-Current Marketable Securities 41,732 47,886
Municipal securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 303 412
Marketable Securities, Debt, Unrealized Gains 0 0
Marketable Securities, Debt, Unrealized Losses (5) (7)
Marketable Securities, Debt, Fair Value 298 405
Cash and Cash Equivalents 0 0
Current Marketable Securities 170 190
Non-Current Marketable Securities 128 215
Mortgage- and asset-backed securities | Level 2    
Marketable Securities [Line Items]    
Marketable Securities, Debt, Adjusted Cost 26,742 24,595
Marketable Securities, Debt, Unrealized Gains 121 175
Marketable Securities, Debt, Unrealized Losses (1,551) (1,403)
Marketable Securities, Debt, Fair Value 25,312 23,367
Cash and Cash Equivalents 0 0
Current Marketable Securities 449 1,278
Non-Current Marketable Securities $ 24,863 $ 22,089
v3.25.1
Financial Instruments - Additional Information (Details)
$ in Billions
6 Months Ended 12 Months Ended
Mar. 29, 2025
USD ($)
Vendor
Sep. 28, 2024
USD ($)
Vendor
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Carrying amount of hedged term debt | $ $ 13.4 $ 13.5
Trade receivables | Credit concentration risk | Cellular network carriers    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Concentration risk, percentage 37.00% 38.00%
Non-trade receivables | Credit concentration risk    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Number of vendors that individually represented 10% or more of total vendor non-trade receivables | Vendor 2 2
Non-trade receivables | Credit concentration risk | Vendor one    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Concentration risk, percentage 49.00% 44.00%
Non-trade receivables | Credit concentration risk | Vendor two    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Concentration risk, percentage 19.00% 23.00%
Hedges of foreign currency exposure associated with revenue and inventory purchases    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Maximum length of time over which the Company is hedging its exposure to the variability in future cash flows for foreign currency transactions 12 months  
Hedges of foreign currency exposure associated with term debt    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Maximum length of time over which the Company is hedging its exposure to the variability in future cash flows for foreign currency transactions 17 years  
Marketable debt securities other than mortgage- and asset-backed securities    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Between 1 and 5 years 83.00%  
Between 5 and 10 years 13.00%  
Greater than 10 years 4.00%  
Mortgage- and asset-backed securities    
Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]    
Between 1 and 5 years 13.00%  
Between 5 and 10 years 10.00%  
Greater than 10 years 77.00%  
v3.25.1
Financial Instruments - Notional Amounts of Derivative Instruments (Details) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Derivatives designated as accounting hedges | Foreign exchange contracts    
Derivatives, Fair Value [Line Items]    
Derivatives, notional amount $ 68,533 $ 64,069
Derivatives designated as accounting hedges | Interest rate contracts    
Derivatives, Fair Value [Line Items]    
Derivatives, notional amount 14,575 14,575
Derivatives not designated as accounting hedges | Foreign exchange contracts    
Derivatives, Fair Value [Line Items]    
Derivatives, notional amount $ 68,388 $ 91,493
v3.25.1
Condensed Consolidated Financial Statement Details - Inventories (Details) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Components $ 2,673 $ 3,627
Finished goods 3,596 3,659
Total inventories $ 6,269 $ 7,286
v3.25.1
Condensed Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Gross property, plant and equipment $ 121,179 $ 119,128
Accumulated depreciation (74,303) (73,448)
Total property, plant and equipment, net $ 46,876 $ 45,680
v3.25.1
Debt - Additional Information (Details) - USD ($)
$ in Millions
Mar. 29, 2025
Sep. 28, 2024
Debt Instrument [Line Items]    
Commercial paper $ 5,982 $ 9,967
Fixed-rate notes, aggregate carrying amount 92,200 96,700
Commercial paper    
Debt Instrument [Line Items]    
Commercial paper 6,000 10,000
Level 2    
Debt Instrument [Line Items]    
Fixed-rate notes, aggregate fair value $ 80,900 $ 88,400
v3.25.1
Shareholders' Equity - Additional Information (Details)
shares in Millions, $ in Billions
6 Months Ended
Mar. 29, 2025
USD ($)
shares
Stockholders' Equity Note [Abstract]  
Number of shares repurchased (in shares) | shares 208
Amount of share repurchases | $ $ 48.3
v3.25.1
Share-Based Compensation - Restricted Stock Unit Activity and Related Information (Details) - Restricted stock units
shares in Thousands
6 Months Ended
Mar. 29, 2025
$ / shares
shares
Number of Restricted Stock Units  
Beginning balance (in shares) | shares 163,326
RSUs granted (in shares) | shares 63,378
RSUs vested (in shares) | shares (39,177)
RSUs canceled (in shares) | shares (4,181)
Ending balance (in shares) | shares 183,346
Weighted-Average Grant-Date Fair Value Per RSU  
Beginning balance (in dollars per share) | $ / shares $ 158.73
RSUs granted (in dollars per share) | $ / shares 228.10
RSUs vested (in dollars per share) | $ / shares 148.90
RSUs canceled (in dollars per share) | $ / shares 177.54
Ending balance (in dollars per share) | $ / shares $ 184.38
v3.25.1
Share-Based Compensation - Additional Information (Details) - Restricted stock units - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total vesting-date fair value of RSUs $ 906 $ 821 $ 9,300 $ 8,600
Total unrecognized compensation cost related to outstanding RSUs $ 26,300   $ 26,300  
Total unrecognized compensation cost related to outstanding RSUs, weighted-average recognition period     2 years 8 months 12 days  
v3.25.1
Share-Based Compensation - Summary of Share-Based Compensation Expense and the Related Income Tax Benefit (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Share-Based Payment Arrangement [Abstract]        
Share-based compensation expense $ 3,226 $ 2,964 $ 6,512 $ 5,961
Income tax benefit related to share-based compensation expense $ (743) $ (663) $ (2,075) $ (1,898)
v3.25.1
Segment Information and Geographic Data - Information by Reportable Segment (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Segment Reporting Information [Line Items]        
Net sales $ 95,359 $ 90,753 $ 219,659 $ 210,328
Operating income 29,589 27,900 72,421 68,273
Americas        
Segment Reporting Information [Line Items]        
Net sales 40,315 37,273 92,963 87,703
Operating income 16,774 15,074 38,283 35,431
Europe        
Segment Reporting Information [Line Items]        
Net sales 24,454 24,123 58,315 54,520
Operating income 10,316 9,991 24,923 22,702
Greater China        
Segment Reporting Information [Line Items]        
Net sales 16,002 16,372 34,515 37,191
Operating income 6,626 6,700 14,786 15,322
Japan        
Segment Reporting Information [Line Items]        
Net sales 7,298 6,262 16,285 14,029
Operating income 3,434 3,135 7,748 6,954
Rest of Asia Pacific        
Segment Reporting Information [Line Items]        
Net sales 7,290 6,723 17,581 16,885
Operating income $ 2,986 $ 2,806 $ 7,570 $ 7,385
v3.25.1
Segment Information and Geographic Data - Reconciliation of Segment Operating Income to the Condensed Consolidated Statements of Operations (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Mar. 29, 2025
Mar. 30, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating income $ 29,589 $ 27,900 $ 72,421 $ 68,273
Research and development expense (8,550) (7,903) (16,818) (15,599)
Operating segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating income 40,136 37,706 93,310 87,794
Segment reconciling items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development expense (8,550) (7,903) (16,818) (15,599)
Corporate non-segment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Other corporate expenses, net $ (1,997) $ (1,903) $ (4,071) $ (3,922)